CHAARTED: QoL Analysis of Docetaxel + ADT in Metastatic Hormone-Sensitive Prostate Cancer

June 3-7, 2016; Chicago, Illinois
Patient-reported outcomes from CHAARTED indicate that adding docetaxel to ADT increased physical symptoms during first 3 months of treatment but was associated with significantly improved QoL at 12 mos in patients with mHSPC.
Format: Microsoft PowerPoint (.ppt)
File Size: 444 KB
Released: June 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), experts discuss advances in prostate cancer treatment, including use of GnRH antagonists and androgen receptor inhibitors.

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD, MPH Released: November 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue